- Home
- TLSI vs CMCM Comparison
TLSI vs CMCM Comparison
Compare TLSI & CMCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- CMCM
- Stock Information
- Founded
- TLSI 2010
- CMCM 2009
- Country
- TLSI United States
- CMCM China
- Employees
- TLSI N/A
- CMCM N/A
- Industry
- TLSI Medical Specialities
- CMCM Computer Software: Prepackaged Software
- Sector
- TLSI Health Care
- CMCM Technology
- Exchange
- TLSI Nasdaq
- CMCM Nasdaq
- Market Cap
- TLSI 160.4M
- CMCM 148.5M
- IPO Year
- TLSI N/A
- CMCM 2014
- Fundamental
- Price
- TLSI $5.62
- CMCM $4.38
- Analyst Decision
- TLSI Strong Buy
- CMCM
- Analyst Count
- TLSI 6
- CMCM 0
- Target Price
- TLSI $11.75
- CMCM N/A
- AVG Volume (30 Days)
- TLSI 66.8K
- CMCM 36.9K
- Earning Date
- TLSI 03-27-2025
- CMCM 03-26-2025
- Dividend Yield
- TLSI N/A
- CMCM N/A
- EPS Growth
- TLSI N/A
- CMCM N/A
- EPS
- TLSI N/A
- CMCM N/A
- Revenue
- TLSI $29,431,000.00
- CMCM $110,544,725.00
- Revenue This Year
- TLSI $55.43
- CMCM $37.71
- Revenue Next Year
- TLSI $50.09
- CMCM $39.26
- P/E Ratio
- TLSI N/A
- CMCM N/A
- Revenue Growth
- TLSI 58.99
- CMCM 20.52
- 52 Week Low
- TLSI $3.50
- CMCM $2.70
- 52 Week High
- TLSI $10.42
- CMCM $6.78
- Technical
- Relative Strength Index (RSI)
- TLSI 55.78
- CMCM 33.91
- Support Level
- TLSI $5.06
- CMCM $4.90
- Resistance Level
- TLSI $5.72
- CMCM $5.07
- Average True Range (ATR)
- TLSI 0.37
- CMCM 0.27
- MACD
- TLSI 0.03
- CMCM -0.05
- Stochastic Oscillator
- TLSI 90.65
- CMCM 8.41
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About CMCM Cheetah Mobile Inc. each representing fifty (50)
Cheetah Mobile Inc along with its subsidiaries provides comprehensive products and services on PCs and mobile devices. It generates revenue from utility-related business, including advertising services and premium membership services. It also provides multi-cloud management platform and overseas advertising agency service. The company operates in two segments: Internet business, and AI and others. The firm's majority of the revenue is derived from the internet business segment that provides mobile advertising services to advertising customers, as well as selling advertisements and referring user traffic on its mobile and PC platforms. Geographically, it derives the majority of its revenue from the PRC and the rest from Hong Kong, Japan, and the rest of the world.